Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers
Anti-CD3 based T cell engager antibodies can redirect cytotoxic activity of T cells in a non-MHC restricted fashion to kill tumor cells effectively. Therefore, the discovery of an anti-CD3 antibody capable of activating T cells in the presence of tumor cells is highly desirable and in recent years, many anti-CD3 bispecific antibodies (bsAbs) entered clinical trials. Here, we showcase the discovery of an anti-CD3 monoclonal antibody (mAb) specific to a unique epitope on the epsilon chain of CD3 originating from the WuXi Biologics advanced hybridoma platform.
This scientific poster was originally presented during the 2023 Chinese Antibody Society Conference